|

PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy

RECRUITINGSponsored by University Hospital, Brest
Actively Recruiting
SponsorUniversity Hospital, Brest
Started2020-06-26
Est. completion2026-06-26
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04272658

Summary

The value of 4D body-to-whole dynamic acquisition in FDG PET / CT to differentiate progression / pseudo-progression during the first therapeutic assessment (PET1) of metastatic melanoma treated with immune checkpoint inhibitors (ICI)to predict the progression of the disease..

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patient old ≥ 18 years
* With metastatic melanoma
* Treated with anti-PD1 : Nivolumab or Pembrolizumab or Combo IPI-Nivo
* Having formulated a non-opposition

Exclusion Criteria:

* \- Minor patient \< 18 years
* Pregnancy or breastfeeding
* Other type of tumor than metastatic melanoma
* Non-eligibility for the examination
* Refusal of participation

Conditions2

CancerMetastatic Melanoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.